drugset
drugset / Trial / NCT03585517

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

NCT03585517 ↗

Phase 1 Completed 10 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML

Timeline

Start
2018-07-21
Primary completion
2020-08-01
Completion
2020-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IM23 Cell therapy — —

Indications

acute myeloid leukemia